BARDA awards up to $70.7M for radiation therapies

HHS's Biomedical Advanced Research and Development Authority awarded five contracts worth up to a total of $70.7 million for the development of therapies to treat acute radiation injuries.

Araim Pharmaceuticals Inc. (Ossining, N.Y.) received $3.1 million for ARA-290, a tissue protective peptide. Nanotherapeutics Inc. (Alachua, Fla.) received up to $31.1 million over five years for NanoDTPA, an oral formulation of chelating agent diethylenetriaminepentaacetate. Neumedicines Inc. (Pasadena, Calif.) received $17 million for HemaMax recombinant human IL-12. RxBio Inc. (Johnson City, Tenn.) received $15 million for Rx100, a small molecule analog of lysophosphatidic acid, an endogenous lipid that activates protective mechanisms of cell survival. ...